Background dose of norepinephrine to reduce the use of positive inotropic drugs after cardiac surgery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300068949

Enrollment

Unknown

Registered

2023-03-02

Start date

2022-03-26

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

norepinephrine group:norepinephrine

control group:normal saline

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40-75 years; 2. ASA Grade II-III, NYHA Grade II-III; 3. Patients scheduled for elective heart valve surgery (including valve plasty and replacement), no gender limit.

Exclusion criteria

Exclusion criteria: 1. Patients who have not signed informed consent; 2. Patients with severe pulmonary diseases (such as moderate and severe COPD); 3. Patients with preoperative hepatorenal insufficiency (Child-Pugh grade B or above; Creatinine >3mg/dL, dialysis); 4. Emergency surgery, re-thoracotomy, simultaneous aortic arch replacement (excluding ascending aorta surgery), simultaneous coronary artery bypass grafting with two or more roots, and operations requiring cryogenic circulation arrest; 5. Patients who have started using norepinephrine or artificial circulation support devices (IABP, ECMO, ventricular assist system, etc.) before surgery.

Design outcomes

Primary

Measure	Time frame
intraoperative positive inotropic drug dosage;dosage of positive inotropic drug 24 hours after operation;	—

Secondary

Measure	Time frame
incidence of perioperative complications;length of stay ICU;time of extubation;length of stay hospital;mortality;	—

Countries

China

Contacts

Public ContactChai Yunfei

707456887@qq.com+86 135 5675 2121

Outcome results